NCT04004403Completed
Alternate Day Fasting, Exercise, and NAFLD
Alternate Day Fasting Combined With Exercise for the Treatment of Non-alcoholic Fatty Liver Disease (NAFLD)
Source: ClinicalTrials.gov · Last updated 25 Sept 2025
Brief summary (registry, in English)
Approximately 65% of obese individuals have non-alcoholic fatty liver disease (NAFLD), and this condition is strongly related to the development of insulin resistance and diabetes. Innovative lifestyle strategies to treat NAFLD are critically needed. The proposed research will demonstrate that alternate day fasting (ADF) combined with exercise is an effective non-pharmacological therapy to treat NAFLD.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 80 (actual)
- First submitted
- 28 Jun 2019
- Start date
- 1 Sept 2019
- Primary completion date
- 1 May 2024
- Lead sponsor
- University of Illinois Chicago
- Diseases
- Obesity, Fatty liver disease (MASLD/MASH)
- NCT number
- NCT04004403
What you commit to
- Study type: Interventional
- Participants enrolled: 80
- From 1 Sept 2019 to the primary completion date, 1 May 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Are not weight stable for 3 months prior to the beginning of study (weight gain or loss \> 4 kg)
- Are taking drugs that induce steatosis (e.g. corticosteroids, estrogens, methotrexate, Ca channel blockers)
- Are taking drugs that benefit NAFLD (e.g. betaine, pioglitazone, rosiglitazone, metformin, or gemifibrozil)
- Are taking drugs that influence study outcomes (weight loss medications)
Other illness
- Have chronic liver disease other than NAFLD (hepatitis B or C, primary biliary cirrhosis, sclerosing cholangitis, autoimmune hepatitis, hemochromatosis, Wilson's disease, α1-antitrypsin deficiency)
- Have a history of known cardiovascular, pulmonary or renal disease
- Are claustrophobic or have implanted metallic/electrical devices (e.g. cardiac pacemaker, neuro-stimulator)
Other
- Consume excessive amounts of alcohol women: 70 g of ethanol (5 alcoholic drinks per week) and men 140 g of ethanol (10 drinks per week) in the past 6 months)
- Diagnosed T1DM or T2DM
- Are perimenopausal or have an irregular menstrual cycle (menses that does not appear every 27-32 days)
- Are pregnant, or trying to become pregnant
- Are smokers
Who the study is looking for
- Age between 18 to 65 years old
- BMI between 30.0 and 59.9 kg/m2
- NAFLD (hepatic steatosis ≥ 5% confirmed by MRI-PDFF)
- Sedentary (\<20 min, 2x/week of light activity at 3-4 metabolic equivalents (METs) for 3 mo prior to study)
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Illinois Chicago Coordinator of this site? Confirm its status | Chicago | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.